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it has been a fruitful year in hypertension research, with
any important publications since the previous review of
he year in hypertension (1). This review distills some of the
ost important developments in the field of hypertension in
he past year that will impact on the diagnosis and treatment
f blood pressure (BP), as well as reviews some of the
merging concepts that will shape the approaches to treat-
ent in the years to come.
easurement of BP
undamental to the accurate diagnosis of hypertension is
he method used to measure BP. Although office BP
easurements have been the reference standard for many
ears, there is increasing use of self measurement of BP at
ome and 24-h ambulatory blood pressure measurement
ABPM). Unlike traditional office BP measurements,
BPM provides data on circadian variations of BP and the
elative importance of nighttime versus daytime BP. In
ddition, disparities between office BP and ABPM have led
o the concept of white-coat hypertension (i.e., BP elevated
n the office but normal by ABPM), and more recently,
asked hypertension (i.e., BP that is normal in the office
ut elevated by home BP measurement or ABPM). Impor-
ant new information related to all of these issues and their
rognostic significance has emerged in the past year.
iagnostic thresholds using 24-h ABPM. These were
evisited in a major study of ABPM in 5,682 participants
mean age 59.0 years, 43.3% women) in prospective popu-
ation studies from Europe and Japan (2). Multivariate
nalyses were used to establish the ABPM thresholds,
hich yielded a 10-year cardiovascular risk similar to that
ssociated with optimal (120/80 mm Hg), normal (130/85
m Hg), and high (140/90 mm Hg) office BP measure-
ents over a median follow-up of 9.7 years. After rounding
he data, the approximate optimal 24-h average ABPM
ystolic/diastolic threshold was 115/75 mm Hg. The opti-
al daytime average was 120/80 mm Hg, and for nighttime
as 100/65 mm Hg. Rounded thresholds for normal BP by
rom the Department of Cardiovascular Sciences, University of Leicester School of
edicine, Leicester, United Kingdom. Dr. Williams has received grant support for
nvestigator-led research and honoraria for lectures and consultancy from numerous
harmaceutical companies in the field of hypertension.e
Manuscript received February 11, 2008; revised manuscript received March 6,
008, accepted March 12, 2008.BPM were 125/75, 130/85, and 110/70 mm Hg, respec-
ively, and those for hypertension by ABPM were 130/80,
40/85, and 120/70 mm Hg, respectively (Table 1). These
ata suggest that population-based outcome-driven thresh-
lds for optimal and normal ABP are lower than those
urrently proposed by international hypertension guidelines.
ome BP measurements— how often? How often should
ome BP be measured to obtain a standardized average for
se in clinical practice? The authors of a recent study from
apan concluded that the average of single measurements
wice per day (morning and evening) for 7 days was
ufficient (3). However, an excellent accompanying editorial
eviewed the dilemmas associated with standardizing the
ssessment of home BP measurement (4) and concluded
hat the recommendations of the European Society of
ypertension Working Group on Blood Pressure Monitor-
ng should still be followed (5). Notably, duplicate morning
nd evening home BP measurements daily for 7 days. The
easurements taken on the first day should be discarded,
eaving at least 24 measurements to be averaged to obtain
he home BP average.
he prognostic significance of office BP, home BP, and
BPM elevations. A common question relates to the
ignificance of elevations of BP via one method but not
nother. A recent study addressed this important issue.
ffice BP, home BP, and ABPM were recorded between
990 and 1993 in 2,051 people, and the individual and
ombined significance of these pressures with regard to
ardiovascular outcomes was determined over 12 years of
ollow-up (6). Using a normal office and 24-h ABPM value
s a reference, the hazard ratio for cardiovascular death
rogressively increased in those with an isolated office BP
levation (white-coat hypertension) or an isolated increase
n 24-h ABPM (masked hypertension). Thus, white-coat
ypertension and masked hypertension are not innocent
ntities, and those with elevations of BP recorded by all 3
easurement methods are at the highest risk of all (6).
asked hypertension. This is defined as an elevated
BPM reading or home BP average but a normal office BP.
t may occur in 10% to 30% of patients and was recently
hown to carry a worse prognosis than white-coat hyper-
ension (high office BP but normal ABPM or home BP)
ith regard to the development of atherosclerosis (7). Thus,
t is important to recognize that a normal office BP does not
xclude hypertension. Moreover, as home BP measurement
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Year in Hypertension May 6, 2008:1803–17ecomes more popular, the detection of masked hyperten-
ion will increase. This diagnosis should be considered in
atients who have clinical evidence of target organ damage
ut in whom office BP appears normal.
entral aortic pressure. Data from the CAFE (Conduit
rtery Function Evaluation) study showed that different
lasses of BP-lowering drugs have a differential effect on
rachial versus central aortic systolic and pulse pressures (8),
nd that central pressures may be a better predictor of
ardiovascular outcomes in response to treatment when
ompared with brachial BP (8). Subsequently, data from the
trong Heart study have also shown that central aortic
ressures may be a better predictor of target organ damage
nd outcomes than conventional brachial pressures (9). So
hould the assessment of central aortic pressures become a
outine feature of the evaluation of the BP-modulating
ctions of drug therapies? The essence of this debate was
aptured in a recent consensus statement on central pressure
easurements (10).
he Origins of Hypertension
diposity—an incubator for hypertension. There is little
oubt that adiposity in young people predicts the risk of
eveloping hypertension and associated metabolic risk fac-
ors. Longitudinal data from the Bogalusa Heart study
racked the association between obesity in childhood and
he risk of developing hypertension (11). Excess adiposity,
efined by a body mass index (BMI) or waist circumference,
as present in one-fifth of those with normal BP, one-third
f those with pre-hypertension, and more than one-half of
hose with hypertension. Moreover, these associations were
vident in people as young as 4 to 11 years of age. These
ata suggest that the avoidance of obesity could markedly
educe the prevalence of hypertension in middle-aged
dults. In support of the strength of the association between
MI and the risk of developing hypertension, a study of
6,424 Israel Defense Forces employees (mean age approx-
mately 35 years) reported that BMI was the strongest
redictor of pre-hypertension, with a 10% to 15% increase
n risk for every 1 kg/m2 increase in BMI (12). Recent
tudies have also highlighted that young people with pre-
ypertension already have evidence of endothelial dysfunc-
ion (13) and cardiovascular structural damage (14,15).
linical significance of pre-hypertension. A study of
0,000 women followed up for 7 years in the Women’s
ealth Study in the U.S. showed that pre-hypertension was
Proposed Outcome-Driven ReferenceValue for Ambulatory Blood Pressure Measurem
Table 1 Proposed Outcome-Driven ReferencValues for Ambulatory Blood Pressu
24
Optimal blood pressure, mm Hg 115
Normal blood pressure, mm Hg 125
Ambulatory hypertension, mm Hg 130
Reprinted, with permission, from Kikuya et al. (2).ssociated with an almost doubling in risk of any cardiovas- aular event, including death, myocardial infarction, stroke,
r hospitalization for heart failure, when compared with
hose with normal BP (16). This risk in part relates to the
levated BP but also reflects the common association of
re-hypertension with features of the metabolic syndrome.
n this regard, it was also reported that pre-hypertension is
ore common in people with diabetes and is associated
ith an almost 4-fold increase in risk of cardiovascular
isease when compared with people without diabetes and
ormal BP (17).
A key question is whether earlier intervention with
ifestyle intervention and/or BP-lowering therapy in
ounger patients would regress early structural damage and
revent further evolution of vascular structural changes. In
his regard, a recent study of BP lowering in people with
re-hypertension showed improvement in markers of vas-
ular damage (18). The importance of this kind of study is
he acknowledgement that if we are to be effective at prevent-
ng the evolution of BP-mediated cardiovascular disease, rather
han just treating the consequences of established damage, then
reatment (lifestyle change and drug therapy) needs to begin
arlier than currently advocated, and if drugs are used then they
hould be metabolically benign (19).
rterial Structure and Function in Hypertension
emodeling of small arteries linked to increased risk of
ardiovascular disease and death. A previous study of
atients with hypertension has suggested that the inward
utrophic remodeling of small arteries (resistance arteries),
ne of the earliest characteristics of hypertensive vascular
tructural change, is predictive of future cardiovascular
vents (20). A more recent study showed a clear link
etween an increased media/lumen ratio of small arteries
rom people with hypertension and an increased risk of
ardiovascular events over a subsequent mean follow-up of
0 years (21). This remodeling link is most likely explained
y the fact that such structural change is occurring through-
ut the cardiovascular system, as illustrated by the recent
eports of an inverse relationship between BP status and
oronary flow reserve (22) and between retinal arteriolar
tructural change and structural change elsewhere, that is,
eft ventricular hypertrophy (LVH), and the link between
etinal vascular structural change (especially arteriolar nar-
owing) and the risk of death from ischemic heart disease
easurement
Daytime Nighttime
120/80 100/65
130/85 110/70
140/85 120/70ent
e
re M
h
/75
/75
/80nd stroke (23).
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May 6, 2008:1803–17 Year in Hypertensionndices of large artery stiffness and cardiovascular out-
omes. Adult ageing is associated with a progressive in-
rease is systolic BP, a reduction in diastolic BP, and a
idening of pulse pressure, consistent with a reduced
ompliance of large conduit arteries. It is has been assumed
hat this stiffening process arises as a consequence of
ypertension-mediated damage to elastic components of the
rterial wall. However, it is also conceivable that inherent
ifferences in arterial stiffness play a primary role in the
evelopment of systolic hypertension. In this regard, a
ecent report from Japan showed that brachial-ankle pulse
ave velocity as an index of arterial stiffness predicted the
ikelihood of progression of BP status in younger patients
ver a 3-year period, from optimal through pre-
ypertension to overt hypertension, thereby identifying
rterial stiffness as an independent predictor for the devel-
pment of hypertension (24). Increased arterial stiffness also
eems to be more common in people with white-coat
ypertension (25). Furthermore, other studies using an
mbulatory arterial stiffness index as an index of arterial
tiffness derived from ABPM identified arterial stiffness as
n independent risk marker for target organ damage, cog-
itive function, and cardiovascular and renal outcomes
26–30).
ypertension and the Heart
VH. Left ventricular hypertrophy is associated with in-
reased risk of cardiovascular morbidity and mortality in
eople with hypertension. Most of the data on this relation-
hip have been derived in white Caucasian subjects. A
ecent large study from Northern Manhattan confirmed that
VH in Hispanic subjects had an approximately 3-fold
ncreased risk of cardiovascular events when comparing
hose in the lowest and highest quartiles of left ventricular
LV) mass (31).
The association between traditional cardiovascular risk
actors and the development of LVH has been clarified
sing magnetic resonance imaging to quantify LV mass and
unction in a population of 4,869 patients (mean age 62
ears) without clinical cardiovascular disease. After adjust-
ent for sociodemographic variables and height, higher
ystolic BP, increased BMI, diabetes, and current smoking
ere all associated with an increased LV mass and lower
troke volume and ejection fraction (32). Similar associa-
ions with an inappropriate LV mass were also reported
rom another study (33). As well as the BP load over 24 h,
he rate of BP variation, that is, steeper BP oscillations, also
eems to be an important determinant of LV wall stress and
VH (34), perhaps reflecting a stiffer cardiovascular system
ith less capacity to smooth variations in stroke volume.
Electrocardiographic (ECG) LVH is recognized to be a
arker of poorer prognosis in people with hypertension. A
ecent study showed that LVH associated with a strain
attern on the ECG is associated with an even worse
rognosis (35). A prolonged QRS duration is also associated tith greater LV mass, more wall motion abnormalities, and
ther markers of target organ damage in hypertensive patients,
erhaps explaining why ECG QRS duration was shown to
redict congestive heart failure (CHF) risk in a cohort of the
ramingham population initially free of CHF (36).
V functional impairment in hypertension. Recent find-
ngs suggest that diastolic and systolic function in people
ith hypertension is impaired earlier than anticipated in the
volution of hypertensive injury (37). The study used tissue
oppler imaging to derive systolic and diastolic velocities
rom the mitral annulus—a recognized early marker of
ubclinical LV dysfunction. The study reported a continu-
us relationship between reduced mitral annulus systolic
nd diastolic velocities with increasing LV mass in people
ith hypertension, beginning at LV mass values clearly
ithin the current normal range (37). A study subsequently
xamining the impact of antihypertensive therapy on dia-
tolic function in people with hypertension was evaluated
ver 38 weeks. There was improvement in diastolic relax-
tion time with BP lowering, but there was no obvious
rug-specific benefit in this short-term study comparing an
ngiotensin receptor blocker (ARB) with treatment that
voided inhibition of the renin-angiotensin system (RAS),
llustrating that BP lowering is overwhelmingly important
o improving diastolic function, irrespective of the presence
f LVH, baseline BP, or age (38).
eft atrial (LA) size. There has been recent interest in LA
ize in hypertension and its prognostic significance for the
evelopment of atrial fibrillation (AF). It is clear that AF is
ore likely to develop in hypertensive patients with LVH
nd an increased LA size. Evidence from recent trials with
egard to the prevention of AF with angiotensin receptor
lockade was recently reviewed (39). Of related interest, the
athophysiological determinants of LA size, methods of
ssessment, and prognostic significance of LA size were also
omprehensively reviewed (40).
In light of the aforementioned associations between the
agnitude of LV structural changes and the functional and
lectrophysiological consequences, it is reassuring that more
ffective regression of ECG LVH with antihypertensive
herapy reduces the risk of developing AF (41) and also
educes the risk of sudden cardiac death (42).
P and heart failure. There has been recent interest in the
elationship between BP and heart failure in 2 contexts.
irst, the prognostic significance of systolic BP and out-
omes in patients admitted to hospital with acute heart
ailure, and second, BP as a risk factor for the development
f heart failure. In a major study of over 48,000 patients
dmitted with acute heart failure in the U.S., patients in the
owest quartile of systolic pressure 120 mm Hg had the
ighest in-hospital and 3-month post-discharge mortality
ate (43). These findings of systolic BP as an important
rognostic indicator for people admitted to hospital with
cute heart failure, consistent with previous studies that
ave reported adjusted relative risks for mortality from 0.78
o 0.90 for each 10-mm Hg increase in SBP (44).
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Year in Hypertension May 6, 2008:1803–17It is well accepted that elevated BP is a risk factor for the
evelopment of CHF. However, the diurnal pattern of BP
ay also be important. In a prospective community study
rom Sweden in relatively healthy men, free of LVH, heart
ailure, or vascular disease at baseline, an increased nocturnal
ressure on ABPM, especially when associated with “non-
ipping” of nocturnal BP, conveyed additional risk of
eveloping CHF beyond conventional office BP measure-
ents (45). It is intriguing to speculate whether more
ffective interventions to lower nocturnal BP would ulti-
ately provide greater protection against the development
f CHF.
ypertension and Stroke
he treatment of hypertension in patients with ischemic
troke and hemorrhagic stroke has been specifically ad-
ressed in 2 recent comprehensive guidelines (46,47). Both
uidelines acknowledge the great uncertainty that remains
bout when and how to optimally intervene with BP-
owering treatment in the setting of acute ischemic or
emorrhagic stroke.
With regard to acute ischemic stroke, a number of
mportant therapeutic conundrums are discussed in detail
46) and the guideline panel concludes that definite answers
o the key questions about the clinical management of BP in
he acute stroke setting are not available. However, prag-
atic recommendations are provided and the guideline
anel did suggest that emergency treatment to lower BP
ould be indicated when systolic BP 220 mm Hg and/or
iastolic BP 120 mm Hg and that BP lowering should be
autious, aiming for a 15% to 25% reduction in the first day.
or those patients who were previously treated for hyper-
ension, treatment should generally be reinstated, usually
pproximately 24 h after the acute event (46).
With regard to spontaneous intracerebral hemorrhage
ICH) (47), BP is correlated with increased intracerebral
ressure (ICP) and volume of hemorrhage. However, it is
nknown whether this relationship is a cause or a conse-
uence, and indeed, it could be either in different settings.
here has also been concern that overaggressive lowering of
P, particularly in the setting of a raised ICP, might result
n enhanced damage in the ischemic penumbra, that is, the
dematous region around the hemorrhage. The case for BP
owering is strongest for those bleeding from a ruptured
ntracerebral aneurysm or arteriovenous malformation, in
hom the risk of rebleeding is highest. However, whether
ore aggressive control of BP in the first few hours after
CH can reduce bleeding without compromising brain
erfusion is still unclear. If systolic BP 200 mm Hg or
ean arterial pressure 150 mm Hg, then aggressive BP
owering is recommended with intravenous therapy (47).
his approach may also be warranted at lower BP levels
ith careful monitoring of ICP (4). Sechanisms of enhanced stroke risk in hypertension.
troke risk increases in people with stiff conduit arteries,
nd this is likely to be a key mechanism accounting for an
ncrease in ischemic stroke risk with age. The endogenous
itric oxide (NO) synthase inhibitor, asymmetric dimethyl-
rginine (ADMA), increases vascular tone and functional
tiffness in cerebral blood vessels. A study examined the
mpact of systemic subpressor dose of ADMA on arterial
tiffness and cerebral perfusion in humans. This study
howed that subpressor doses of ADMA increase vascular
tiffness and decrease cerebral perfusion in healthy subjects,
mplying a potentially important role for vascular stiffness in
he pathogenesis of cerebrovascular disease (48). Another
tudy showed that arterial stiffening with age results in a
eduction in carotid flow velocity but a marked increase in
arotid systolic and pulse pressures, attributable to greater
ystolic pressure augmentation with age and arterial stiffen-
ng. These changes could account for enhanced risk of
icrovascular damage in the brain in older hypertensive
atients (49).
These observations may provide a basis for more effective
odulation of cerebral pressures by reducing the late systolic
ugmentation. Consistent with the aforementioned obser-
ations regarding ADMA, one way of doing this might be
he use of drugs that enhance NO availability in the vessel
all, such as NO donors. A recent study examined the effect
f the NO donor glyceryl trinitrate, administered via a
ransdermal patch, on cerebral blood flow (CBF) and
erebral perfusion pressure (CPF) in patients with recent
troke (50). They showed that glyceryl trinitrate lowered
entral systolic BP by 22 mm Hg but did not alter global
BF or CBF or CPF to the contralateral or ipsilateral
emispheres, or the area of stroke oligemia, penumbra, or
ore. Thus, the treatment was effective at reducing cerebral
ressures without inducing cerebral steal. Clearly, these
ndings provide a pathophysiological basis for studies of the
se of NO donors in acute ischemic stroke and in the
revention of stroke. With regard to the latter, the challenge
ill be to develop the means of delivering NO on a
onsistent basis, in sufficient quantities, without the devel-
pment of tolerance.
Moving away from the acute stroke setting, a recent
omprehensive review of the treatment of hypertension for
he primary and secondary prevention of stroke concluded
hat the most important determinant of outcome was the
uality of BP control, and that BP control usually remains
uboptimal (51). This was underscored by a 5-year
ollow-up of patients who had suffered their first stroke in
ustralia; 82% of patients after suffering their first stroke
ere hypertensive, and that BP control remained subopti-
al in 30% and the patient was unaware of their hyperten-
ion in 7% (52).
P and cognitive function. Another important aspect of
rain protection is the prevention of cognitive decline. The
reatment of hypertension in the Honolulu Asia Aging
tudy of Japanese American men followed up since 1965
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May 6, 2008:1803–17 Year in Hypertensionhowed that the treatment of hypertension substantially
educed the risk of dementia by as much as 60% when
ompared with those with never-treated hypertension. Im-
ortantly, the benefit accrued in proportion to years of
reatment, thus the earlier the treatment starts, the better
53). Another European study of elderly men with treated
ypertension showed a similar reduction in risk of cognitive
mpairment and dementia when compared with untreated
atients (54). These studies highlight the importance of
ypertension in the pathogenesis of cognitive decline and
ementia, and the power of effective treatment of BP to
revent it—this will become especially important as our
opulations age and focus shifts toward strategies to pre-
erve cognitive function.
ypertension and the risk of developing new-onset
iabetes. It is well recognized that people with hyper-
ension have an increased risk of developing diabetes,
ven when untreated. It is also recognized that this risk
an be further influenced by antihypertensive therapy. A
ong-term follow-up study of patients from Sweden
valuated the risk of developing diabetes in a cohort of
54 men with hypertension, ages 47 to 54 years, screened
or cardiovascular risk factors and followed up for 25 to
8 years (55). A total of 148 (20%) treated hypertensive
atients developed diabetes during 25 years, and in a
ultivariate Cox regression analysis, body mass index,
erum triglycerides, and treatment with beta-blockers
ere positively related with the development of new-
nset diabetes. Importantly, the development of new-
nset diabetes was associated with an increased risk of
troke (hazard ratio [HR] 1.67), myocardial infarction
HR 1.66), and mortality (HR 1.42). The time from
nset of new diabetes to stroke or myocardial infarction
as approximately 9 years. This is important because
linical trials are usually of shorter duration than this and
ost likely underestimate the enhanced cardiovascular
isk associated with the development of new-onset dia-
etes. In another study, a network meta-analysis was used
o assess the risk of developing new-onset diabetes with
ifferent treatment strategies for hypertension (56). A
etwork meta-analysis makes a number of assumptions,
hat is, if drug A causes more diabetes than drug B, and
rug B more than drug C, then it is assumed that drug A
ill cause more diabetes than drug C. Initial treatment
ith a diuretic was the reference standard for the com-
arison of the various drug classes. As shown in Figure 1
56), the association of antihypertensive drugs with
ncident diabetes was lowest with ARBs and angiotensin-
onverting enzyme (ACE) inhibitors, followed by cal-
ium channel blockers (CCBs) and placebo, beta-
lockers, and diuretics in rank order. Together, these
tudies suggest that the risk of developing new-onset
iabetes: 1) is influenced by the class of antihypertensive
herapy used to lower BP, 2) is more likely in people with
besity, an elevated baseline blood glucose level, and
eatures of the metabolic syndrome, and 3) is associated gith an enhanced risk of developing major cardiovascular
omplications, if patients are followed up long enough for
hem to occur.
enetics of Hypertension
n industry has grown around the genetics of hypertension,
nd there have been some spectacular discoveries of specific
ene defects associated with rare causes of hypertension
e.g., Liddle and Gordon syndromes). Crucially, where
rogress has been made, the phenotype has been distinct.
ackling the genetic basis of essential hypertension would
redictably be more of a challenge because the condition is
eterogenous, the diagnostic criteria are a moving target,
nd there is a very strong lifestyle impact. Furthermore, even
n well-characterized animal models (e.g., the spontaneously
ypertensive rat), fed a mundane diet, and living a standard-
zed lifestyle, identifying a genetic cause has proved elusive.
hus, although the results of the largest ever genome-wide
ssociation study of 7 common diseases (including hyper-
ension) were eagerly awaited by the hypertension geneti-
ists, the results were predictable to many (57). The study
ound no significant gene associations with hypertension. A
umber of reasons for this were discussed, including: 1)
ypertension may indeed have fewer common risk alleles of
arger effect sizes than some of the other complex pheno-
ypes, 2) perhaps common susceptibility variants of large
ffect size were present but remained undetected by the
pecific single nucleotide polymorphism genotype sets used
n this study, and perhaps more extensive screening of the
Figure 1 Network Meta-Analysis of New Onset Diabetes
Associated With Antihypertensive Therapy
Initial diuretic therapy was used as referent agent (open box at odds ratio 
1.00). Size of squares (representing the point estimate for each class of anti-
hypertensive drugs) is proportional to number of patients who developed inci-
dent diabetes. Horizontal lines indicate 95% confidence intervals. Odds ratios
to the left of the vertical line at unity denote a protective effect (compared
with initial diuretic). Individual pairwise comparisons between diuretic versus
beta blocker were not significantly different (p  0.30) and were significantly
more likely to increase the risk of new diabetes when compared with other
treatments, including placebo. ACE  angiotensin-converting enzyme; ARB 
angiotensin receptor blocker; CCB  calcium channel blocker. Reprinted with
permission (56).enome would reveal more, and 3) the problem of accurate
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Year in Hypertension May 6, 2008:1803–17dentification of the hypertensive phenotype and the
ossibility that hypertensive patients may have be mis-
lassified in both the affected and the control populations,
hereby diluting the power of the study. The latter seems
he most likely explanation. Blood pressure classification
as based on office BP measurements—clearly some of
hese patients may have had white-coat hypertension,
nd some of the control subjects may have had masked
ypertension, diluting the power of the study to find
ssociations. It is remarkable that the genetic aspects of
hese studies are so rigorous and elegant and yet the
henotyping is so rudimentary—little progress will be
ade until this is addressed.
ifestyle and Nonphamacological Interventions
odium intake and cardiovascular risk. All international
ypertension guidelines recommend dietary sodium restric-
ion. However, the impact of this strategy on cardiovascular
isease outcomes had been poorly defined until recently
58). This study used data from the long-term follow-up (10
o 15 years) of people originally allocated to 2 randomized,
ontrolled trials of sodium restriction. Those allocated to
odium reduction had a 30% lower incidence of cardiovas-
ular events in the next 10 to 15 years, irrespective of
ender, ethnic origin, age, body mass, and BP. Interestingly,
he people randomized into these studies were not hyper-
ensive (BP approximately 125/85 mm Hg). It is conceiv-
ble that the benefits, impressive as they are, might have
een even greater in a hypertensive population. Importantly,
recent meta-analysis has also highlighted the importance
f salt intake in the genesis of hypertension in children and
he effectiveness of sodium restriction at reducing BP (59).
hese findings reinforce current guideline recommenda-
ions and underscore the importance of education and
ational health policies to reduce dietary sodium.
lcohol and BP. Using data from the National Health and
utrition Examination Survey (NHANES) (1999-2000),
he relationship between alcohol intake and BP for a sample
f the U.S. adult population was examined. An alcohol
ntake of up to 2 drinks per day had no effect on BP.
owever, there was a gender-related effect of alcohol intake
n excess of 2 drinks per day on BP, with increased BP
bserved only in men but not in women (60). Further
nformation on the relationship between alcohol consump-
ion, impact of consumptions patterns, and types of alcohol
onsumed with regard to vascular function and hypertension
ubtypes was provided in a detailed review (61).
leep and BP. Characteristically BP decreases during
leep, and an absence of this nocturnal dip in BP has been
ssociated with an increased risk of cardiovascular events. A
ecent longitudinal analyses of the first NHANES (n 
,810) examined the impact of sleep duration on the risk of
eveloping hypertension (62). This risk was increased by
pproximately 2-fold in adults in middle age who sleep 5
each night. Even after adjusting for obesity and diabetes hthe risk of which also increase with sleep deprivation), the
isk remained approximately 1.6-fold. There are a number
f mechanisms that might account for this relationship; it
ay simply reflect a higher 24-h average BP load and longer
uration of sympathetic nervous system activation as a
onsequence of less time asleep. In turn, this would give rise
o a higher risk of longer-term cardiovascular structural
amage, leading to sustained hypertension. Whatever the
echanism, doctors should consider sleep deprivation in
heir assessment of people developing hypertension.
bstructive sleep apnea (OSA) and hypertension. There
s a clear association between OSA and hypertension. An
pnea-hypopnea index of 15, (i.e., breathing decreases or
tops 15 times per hour of sleep) is associated with a
-fold increase in the risk of developing hypertension (63).
gainst this background, a recent randomized, double-
lind study of patients with hypertension and OSA showed
hat 2 weeks of continuous positive airway pressure (CPAP)
as effective in lowering both nighttime BP and to a lesser
xtent daytime BP when compared with sham CPAP (64).
hese findings further support the concept that chronic
leep disturbance can play a significant role in the patho-
enesis of hypertension. Further studies will be required to
etermine whether such interventions in suitable individuals
re also effective at reducing the risk of cardiovascular events
s well as BP.
iuretic Therapy for Hypertension
lthough thiazide-type diuretics are often viewed as a single
lass, there has been much debate about the relative poten-
ies of different thiazide-type diuretics. This was addressed
n an 8-week cross-over study comparing treatment with
hlorthalidone 12.5 mg/day (force-titrated to 25 mg/day)
nd hydrochlorothiazide 25 mg/day (force-titrated to 50
g/day) in 30 untreated hypertensive patients (65). The
ain outcome was 24-h ABPM assessed at baseline and
eek 8. The decrease in BP was significantly greater with
hlorthalidone 25 mg/day compared with hydrochlorothia-
ide 50 mg/day (24-h mean 12.4/1.8 mm Hg vs.
7.4/1.7 mm Hg); the differences were most notable for
ighttime BP in favor of chlorthalidone. The incidence of
ypokalemia was similar for both treatments. These data
how that chlorthalidone is more effective in lowering
ystolic BP than hydrochlorothiazide, especially at night,
eflecting a longer duration of action. Whether these dif-
erences are clinically important is unknown because there
ave been no head-to-head outcome trials with thiazide-
ype diuretics. However, it is intriguing that the majority of
xed-dose combination therapies that include a thiazide use
ydrochlorothiazide rather than chlorthalidone; perhaps
ombinations with the latter would have been even more
ffective.
iuretics for drug-resistant hypertension. Diuretic ther-
py is increasingly used for the treatment of drug-resistant
ypertension. Low-dose spironolactone was recommended
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May 6, 2008:1803–17 Year in Hypertensions a step 4 treatment option in the British Hypertension
ociety guidelines in 2004 (66). In so doing, the guideline
ommittee acknowledged a lack of clinical trial evidence to
upport this pragmatic recommendation. Spironolactone 25
g once daily was the recommended fourth-line treatment
or patients with uncontrolled BP in the ASCOT (Anglo-
candinavian Cardiac Outcomes Trial) (67). In this setting,
pironolactone, when added to existing therapy, which
nvolved a mean of approximately 3 other drugs, resulted in
n impressive approximately 22/10 mm Hg decrease in BP
nd was generally well tolerated, with 6% of patients
iscontinuing the treatment because of gynecomastia or
reast discomfort and 2% because of hyperkalemia. Almost
dentical decreases in BP approximately 22/9 mm Hg were
bserved in another smaller observational study in which
pironolactone 25 mg daily was added to the treatment of
atients already receiving 3 or more drugs, one of which was
n ACE inhibitor or an ARB (68). In a further retrospective
tudy of 340 patients with uncontrolled BP despite treat-
ent with at least 2 drugs in the U.S., 42 received add-on
pironolactone therapy and the rest received a variety of
ther drugs (69). The decreases in BP in those receiving
pironolactone averaged approximately 23.13 mm Hg,
hich was significantly greater than the decrease in those
eceiving other treatments, approximately 8/6 mm Hg.
Together, these data suggest that with appropriate mon-
toring of serum potassium and sodium levels and prior
xclusion of patients with significant renal impairment, the
ddition of low-dose spironolactone therapy can be very
ffective at producing significant reductions in BP in people
ith drug-resistant hypertension. In those patients in whom
his strategy is effective but the spironolactone is poorly
olerated because of breast discomfort, my practice is to use
igh-dose amiloride (typically 20 mg/day), or higher doses
f thiazide-type diuretics. Further studies are required to
uild on these observations and define the optimal treat-
ent strategies for patients with patients with drug-
esistant hypertension.
hiazide diuretics: hypokalemia and glucose metabo-
ism. Thiazide diuretics are associated with an increased
isk of developing diabetes in some people with treated
ypertension. A long-held view has been that the underly-
ng mechanism is related to diuretic-induced hypokalemia.
his hypothesis was explored in a quantitative review of the
elationship between thiazide-induced hypokalemia and
lucose intolerance (70). The study used data from 59
linical trials involving 83 thiazide diuretic study arms. The
ndings suggested that thiazide-induced hypokalemia was
ssociated with increased blood glucose. This observation is
ntriguing and raises many thoughts. To my knowledge,
here have been no studies that have formally reported a
elationship between hypokalemia and incident diabetes in
ypertension outcome trials—presumably this could be
nalyzed. Moreover, if thiazide-induced increases in blood
lucose are driven by hypokalemia, then why has no
elationship between chronic hypokalemia (e.g., in Conn ryndrome or Gittleman syndrome) and impaired glucose
olerance or risk of incident diabetes been reported? More-
ver, could the protective effect of ACE inhibition or ARBs
gainst the development of diabetes simply be a function of
heir capacity to increase serum potassium, or limit its
ecrease when used in combination with diuretics? In this
egard, would the use of potassium-sparing diuretics in
ombination with thiazides reduce the risk of developing
iabetes?
It is remarkable that as we enter the 50th anniversary of
he launch of thiazide diuretics for the treatment of hyper-
ension, so many fundamental questions remain unan-
wered. There is little doubt that novel, more effective, and
etter tolerated diuretic-based treatments could still emerge
hen clinical science rises to the challenge.
ew Treatments and New Targets
here are already many effective drugs for the treatment of
ypertension. It is therefore exciting to witness the emergence
f new classes of drugs in a challenging market. The burden of
isease is enormous, and it is unlikely that all therapeutic
argets have been exhausted by existing treatments.
irect renin inhibition. The renin system has been a
opular target for drug therapy for hypertension dating from
he discovery of the first ACE inhibitor, captopril, in 1977
nd the first ARB, losartan, in 1988. Now the first direct
enin inhibitor (DRI) for clinical use (aliskiren) has
merged. Renin was in fact the first target for inhibiting the
enin system, with the description of pepstatin in 1971.
owever, progress in drug development was hampered by
he fact that the first inhibitors were peptide analogues that
ad to be administered parenterally. The first orally active
gents were bedeviled by problems of poor bioavailability
2%), a short half-life, and poor BP-lowering efficacy (for
eview see reference 71). Eventually, aliskiren emerged as
he first nonpeptide, orally active renin inhibitor to be
aunched as treatment for hypertension. Aliskiren has high
pecificity for renin and is a potent renin inhibitor. It still
as low bioavailability (approximately 3%) but has a long
alf-life (approximately 24 h), which is attractive for the
nce-daily treatment of hypertension. Aliskiren is not me-
abolized by the cytochrome p450 system and is primarily
liminated unchanged in the bile, with 1% excreted in the
rine. There seem to be no clinically important pharmaco-
inetic interactions. The adverse effect profile looks similar
o placebo in phase II trials in humans, the main adverse
ffect being diarrhea at high doses, that is, at 600 mg/day,
hus the recommended maximum dose is 300 mg/day (72).
t these doses, aliskiren in monotherapy seems to have
imilar BP-lowering efficacy as other therapeutic approaches
o blockade of the renin system. However, there are differ-
nces in the neurohumoral profile in response to blockade of
he renin system with these different treatment strategies
Table 2). This has led to much speculation about the
elative merits of each approach (73).
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Year in Hypertension May 6, 2008:1803–17The most intense debate with DRIs has been about the
ole of pro-renin, the level of which increases after treat-
ent with DRIs. Elevated pro-renin levels have been
onsidered as a possible mediator of target organ damage
ecause of an association in a number of studies between
levated pro-renin levels and diabetic microvascular disease
nd nephropathy. This area is complex, and recent data
uggest that pro-renin may bind to a renin/pro-renin
eceptor that has been localized to the heart, liver, brain, and
idney. In vitro studies have suggested that binding of
ro-renin to this receptor can generate angiotensin at the
ell surface, supporting the hypothesis of increased tissue
ctivation of RAS in the presence of high pro-renin levels.
t has been suggested that the binding of aliskiren to the
ocket in the prorenin/renin molecule may lead to a
onformational change that prevents pro-renin binding to
he receptor, thereby preventing tissue activation of RAS
for review of mechanisms, see reference 74). This hypoth-
sis clearly needs testing in large-scale trials, and targeting
he prevention of diabetic nephropathy and microvascular
isease in this regard seems an attractive proposition.
With the availability of different methods of inhibiting
he renin system, another concept that has been investigated
s whether combining the DRI with another means of
nhibiting the renin system, for example an ARB, in
aximum recommended doses would be more effective than
onotherapy with either at lowering BP. The combination
f DRI and ARB was more effective at lowering 24-h
mbulatory BP than either the DRI or ARB alone (approx-
mately 4/3 mm Hg greater decrease in BP with the
ombination), with no significant increase in adverse effects
ith the combination (75). Moreover, the incidence of renal
mpairment or hyperkalemia was low in this group. There is
ittle evidence to suggest that increasing the dose of the
RB or DRI beyond their recommended maximum would
ave achieved this magnitude of additional BP lowering,
lthough few such studies have used ABPM to document
he BP response. It should be added that the BP response to
his combination is less than would be expected from
ombing the DRI with a thiazide diuretic or a CCB. So
rom a pure BP-lowering perspective, the DRI/ARB com-
ination is unlikely to be the most effective option. How-
ffects of Inhibitors of the Renin System on Enzymes, Substrates,
Table 2 Effects of Inhibitors of the Renin System on Enzymes,
Enzymes
PRA PRC Angiotensinogen
Beta-blockers 2 2 NA
Renin inhibitors 2 1 NA
ACE inhibitors 1 1 2
ARB 1 1 2
ACE inhibitors plus ARB _ _ +
Renin inhibitors plus ARB 2 _ NA
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; NA  data not availa
Adapted from Staessen et al. (71).ver, if the speculated benefits of more complete blockade of ehe renin system for target organ protection are real, then
his may be the preferred strategy, both from a neurohu-
oral perspective and from a side effect profile—future
rials will reveal all!
So, when to use DRIs for people with hypertension?
hey are likely to be as effective at lowering BP in
onotherapy as other means of inhibiting the renin system,
hat is, ACE inhibition or ARBs, but with less side effects
han ACE inhibition. The contraindications to their use are
imilar to other forms of RAS blockade. DRIs are likely to
e especially effective in younger white patients who in
eneral have a more active renin system, and in any patients
eceiving diuretics or CCBs, in whom their renin system
ill have been activated. They may also ultimately develop
role in other areas in which inhibition of the renin system
as been effective, notably in heart failure and renal disease.
he challenge will be to convert the promise for enhanced
arget organ protection into evidence.
vaccine for hypertension? Furthering the efforts to
evelop techniques to inhibit the renin system, perhaps one
f the most remarkable reports in the past year was of the
reliminary results from a vaccination development program
o immunize people with hypertension against angiotensin
I (76). A construct of a virus-like particle linked to an
ngiotensin-like peptide was found to be highly immuno-
enic in mice and rats. Its administration to spontaneously
ypertensive rats reduced systolic BP, similar to that with
reatment with an ACE inhibitor (76). The investigators
hen immunized 12 healthy human volunteers with a similar
onstruct to measure the immunogenicity of the antibody to
ngiotensin II. All subjects generated an antibody response,
ut no hemodynamic data were reported from this phase 1
tudy. Although the concept is intriguing, it is worth taking
step back and questioning whether a vaccine approach is
afe and appropriate for people with hypertension, when it
s unlikely to be reversible, could generate immune complex-
ediated disease, and so many excellent therapeutic options
re already available to inhibit the RAS. I would concur
ith the views expressed in the excellent critical editorial of
r. Menard on the subject (77).
cupuncture for treating hypertension? It has been
laimed that the ancient Chinese art of acupuncture is an
nd Products
trates, and End Products
ubstrates End Products
Angiotensin I Bradykinin Angiotensin II Aldosterone
NA NA NA NA
2 NA 2 2
1 1 2 2
1 NA 1 2
_ 1 NA 2
NA NA NA +
A  plasma renin activity; PRC  plasma renin concentration (not including pro-renin).and E
Subs
Sffective treatment for BP. Claims that have recently been
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May 6, 2008:1803–17 Year in Hypertensionubjected to formal clinical trials. The SHARP (Stop
ypertension With Acupuncture Research Program) pro-
pective, double-blind, randomized, sham-controlled,
arallel-group study compared twice-weekly active acu-
uncture with an invasive sham acupuncture for 6 weeks in
92 patients who had been weaned off their BP-lowering
edication 3 weeks previously. The conclusion of the study
as that active acupuncture provided no greater benefit than
he invasive sham procedure (78). Another study reported
he results of a single-blind randomized controlled trial of
60 adult patients with grade 1 or 2 hypertension on stable
P-lowering therapy or no therapy from a single institution.
he participants received BP-specific acupuncture or sham
cupuncture on 22 occasions over 6 weeks. This study used
BPM to record the BP changes and reported that there
as a significant 6 mm Hg greater reduction in ambulatory
ystolic BP at the end of the 6-week treatment period in the
ctive acupuncture group. However, thereafter BP returned
o pre-treatment values within 12 weeks (79). It seems at
est that acupuncture may have a modest BP-lowering effect
ut that this effect may not be seen in all patients and does
ot persist beyond treatment withdrawal, thus continuous
reatment (2 to 3 times per week) would be required to
ustain the BP reduction. This may be a preferable option to
rug therapy for a few patients, but the long-term efficacy is
nknown and would need to be monitored, and recurrent
reatments of this type will be costly and time-consuming. I
annot see it catching on!
oluble guanylate cyclase (sGC) activators. Activation of
GC would be expected to increase cyclic guanosine mono-
hosphate levels in target tissues, resulting in vasodilatation
nd an antiproliferative effect, properties that would be an
ttractive template for novel drug therapy for the treatment
f hypertension. It was recently reported that BAY41-2272,
novel, orally active stimulator of sGC, can lower the BP
nd inhibit the cardiac hypertrophy and fibrosis in rats with
ngiotensin II–induced hypertension (80). I would also
nticipate that this treatment would also reduce large artery
tiffness and would be a particularly effective means of
owering central aortic systolic pressure, beyond the benefits
bserved on brachial BP. The only potential problem might
e the fact that activation of sGC would be expected to
nhibit platelet aggregation and thus prolong bleeding
ime. Although this would be beneficial in some patients,
he impact of sGC activators on bleeding complications
ould be important to evaluate in phase II and III trials.
evertheless, this is an exciting new approach to treat-
ent and has the potential to be a very effective BP-
owering agent for older patients with systolic hyperten-
ion and others with stiff conduit arteries, that is, people
ith diabetes.
argeting the Vascular Wall
dvanced glycation cross-link breakers. Increased stiff-
ning of large conduit arteries with ageing and disease is issociated with a widening pulse pressure and increased
rachial systolic pressure. It is also associated with a central
ortic pressure relative to brachial pressure. A major mech-
nism accounting for the increased vascular wall stiffness
ith ageing is the accumulation of advanced glycation
nd-products (AGEs) within the vascular wall. The AGEs
orm abnormal cross-links with vascular wall collagen,
educing vascular compliance, thereby increasing arterial
tiffness. The AGEs also quench nitric oxide, impairing
ndothelial function, which also increases arterial stiffness.
hus, targeting AGEs and reducing their presence within
he vascular wall seems an attractive option. Such AGE
ross-link breakers as alagebrium chloride previously have
een shown to improve arterial stiffness in aged animal
odels and older humans with systolic hypertension. How-
ver, clinical trials of alagebrium for systolic hypertension
ave been disappointing with regard to brachial systolic
ressure lowering (81). However, this does not preclude an
mportant effect on endothelial function, arterial stiffness,
nd central aortic pressure and hemodynamics, which may
e a more important target. A recent report supports this
oncept from a clinical study of 13 adults, mean age 65
ears, who were administered oral alagebrium twice daily for
weeks (82). This resulted in marked improvements in
ndothelial function (as determined by flow-mediated dila-
ation) and central aortic hemodynamics and pressures,
espite only a small but insignificant decrease in brachial
ressure. It is surely too early to abandon hope of directly
mproving the functional characteristics of the aorta as a
eans of reducing cardiovascular risk. Importantly, brachial
P may not reveal such benefits, and the obsession of
egulators with using brachial BP as the sole arbiter of drug
fficacy in hypertension may prevent the development of
ovel and more effective strategies to reduce risk in these
atients.
arfan syndrome—a paradigm for vascular wall therapy.
natural model of degenerative aortic disease in Marfan
yndrome, an autosomal dominant connective tissue disor-
er caused by mutations in the fibrillin-1 gene (FN1).
arfan syndrome is characterized by progressive aortic
tiffening, dilatation, and rupture. The current recommen-
ation for the treatment of hypertension in Marfan syn-
rome is with beta-blockade because of their effect to reduce
he P/T in the aortic root. It is noteworthy, however,
hat this recommendation is based on a single trial of 32
atients (83). Recent studies have directly implicated the
AS in the pathogenesis of the vascular wall changes in
arfan syndrome via a mechanism that involves transform-
ng growth factor (TGF)-beta. The hypothesis is that FN-1
ormally sequesters TGF-beta and deficiency in FN-1
ecause of its mutation leads to increased activation of
GF-beta. In a mouse model with a FN-1 gene mutation
hat mimics the Marfan syndrome aortic phenotype, an
RB (losartan) was more effective than a beta-blocker
propranolol) at preventing dilatation of the aortic root—
ndeed, the aortas of the animals treated with losartan were
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Year in Hypertension May 6, 2008:1803–17ndistinguishable from those of wild-type controls (84).
hese exciting developments were further evaluated in a
mall double-blind, placebo-controlled trial with an ACE
nhibitor (perindopril) in patients with Marfan syndrome to
easure its impact on aortic stiffness and root diameter over
4 weeks on a background of beta-blocker therapy. The
CE inhibitor reduced aortic stiffness and aortic root
iameter and also reduced systemic markers of TGF-beta
ctivation. (85). There now follows another clinical trial of
oung people with Marfan syndrome comparing a beta-
locker (atenolol) with an ARB (losartan) on progression of
ortic root diameter over 3 years (86). The findings will be
mportant, and whatever the outcome, this series of studies
s an example of translational science at its best.
trategies for improving the control of BP. Beyond the
ocus on monotherapy, a recent study has also highlighted
he possibility of improving BP control by combining multiple
P-lowering drugs in low dose in a single pill (87). This study
ompared the BP-lowering efficacy of a single capsule contain-
ng a quarter of the standard dose of 4 antihypertensive agents
amlodipine, atenolol, bendroflumethiazide, and captopril)
ith standard doses of these agents in monotherapy in a
arallel group design for 4 weeks. The reduction in mean
rterial pressure with the combination of approximately 19 mm
g was significantly greater than that with individual agents,
anging from 6 to 11 mm Hg. This small study establishes
roof of principle for this approach to improving the magni-
ude and reducing heterogeneity in the BP response to therapy.
onger-term studies would be required to establish the toler-
bility of multidrug combinations and to define the optimal
ombination; nevertheless, the concept is an important prag-
atic way to improve the BP response with a single BP-
owering pill.
Another way to improve long-term BP control is to
ncourage patients to continue to take their treatment! A
ecent study assessed the impact of the comprehensive
harmacy care program on medication adherence and BP
nd low-density lipoprotein cholesterol control (88). The
omprehensive pharmacy program consisted of 3 elements:
ndividualized medication education, medications dispensed
sing an adherence aid (blister packs), and regular follow-up
ith clinical pharmacists. Compared with usual care, the
omprehensive pharmacy program substantially improved
edication adherence and the control of systolic BP. How-
ver, it does seem that the intervention needs to be sustained
or the adherence benefit to persist, and thus the cost
ffectiveness of this intervention would need to be evaluated.
o statins reduce BP? Statins are very effective at reducing
he risk of ischemic stroke and heart disease in people with
ypertension. This has prompted the question of whether
tatins may exert some of this benefit by lowering BP. This
uestion was addressed in a comprehensive meta-analysis of
0 trials and 828 patients receiving statin therapy in whom
P was recorded and concomitant BP-lowering therapy (if
ny) remained unchanged during treatment (89). Statins
eemed to exert a small but significant effect on systolic BP t1.9 mmHg) and a nonsignificant effect trend on diastolic
P (0.9 mm Hg). The effect was greatest in those with
igher BP at baseline. The BP response to statins was
nrelated to age, changes in serum cholesterol, or length of the
rial. Whether statins exert a greater effect beyond brachial BP
n central aortic BP will soon be reported from the CAFÉ
Conduit Artery Functional Evaluation) study (90).
ecent clinical outcome trials of BP-lowering therapies.
here are a paucity of data on the impact of BP medications
n cardiovascular outcomes in patients from Asia. The Jikei
eart study contributed to the database with a randomized
ontrolled trial, using a prospective randomized open
linded endpoint design, conducted in Japan (91). This
tudy recruited 3,081 patients (mean age 65 years) who were
eceiving conventional treatment for hypertension and had
oronary heart disease, heart failure, or a combination of
hese disorders. In addition to their conventional drug
reatment (not including an ARB), the patients were ran-
omly assigned to an ARB, valsartan (mean dose 75
g/day) or other treatment, avoiding the use of an ARB.
he primary end point was a composite of cardiovascular
orbidity and mortality. At baseline, 67% of the patients
ere receiving a CCB, 35% an ACE inhibitor, 32% a
eta-blocker, and approximately 10% a diuretic. The base-
ine BP was 139/81 mm Hg. After a median follow-up of
.1 years, the primary end point was significantly reduced by
9% in the group assigned to valsartan, mainly because of a
ower incidence of incidence of stroke and transient isch-
mic attacks, angina pectoris, and heart failure. There was
o difference in mortality, and the effects on myocardial
nfarction and renal end points were neutral. Office BP at
he end of the trial was similar in both groups, approxi-
ately 132/77 mm Hg. So, how can the results of the Jikei
eart study be explained and reconciled with the results of
he VALUE (Valsartan Antihypertensive Long-Term Use
valuation) study (92), in which CCB-based treatment
with amlodipine) was associated with fewer myocardial
nfarctions and strokes when compared with therapy based
n the ARB valsartan? In the VALUE study, the CCB-
ased therapy produced more effective BP lowering, espe-
ially in the early phase of the study, and this is the most
ikely mechanism accounting for the superiority of the
CB, especially at preventing stroke—the simple but im-
ortant message is that putative drug-specific benefits of
P-lowering drugs can rarely if ever overcome superior BP
ontrol with regard to preventing major cardiovascular
isease (CVD) events in large-scale clinical trials, it simply
oes not happen. In support of this conclusion, a recent
ost-hoc analysis of the VALUE trial that examined only
hose patients who remained on monotherapy was reported.
his was interesting because the BP in the valsartan versus
mlodipine treatment arms were similar throughout the
rial, and in this case there was no difference in major
utcomes, apart from heart failure, which was more effec-
ively reduced by the ARB as expected (93). With regard to
he Jikei heart study and mechanisms, it is also noteworthy
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May 6, 2008:1803–17 Year in Hypertensionhat the baseline treatment with RAS blockade (approxi-
ately one-third) was relatively low in this population at
igher risk of CVD, and it is conceivable that the better
overage with blockade of the RAS in valsartan arm of the
ikei heart study provided the added protection beyond
rachial BP. In this regard, it is also possible that more
ffective lowering of central aortic pressure in the valsartan
rm could have driven some of the benefit, although this
emains speculative in the absence of data on central aortic
emodynamics.
Further analyses of the ALLHAT (Antihypertensive and
ipid-Lowering Treatment to Prevent Heart Attack Trial)
lso emerged in the past year when data from a comparison
f outcomes in the CCB (amlodipine, n  9,048) versus
CE inhibitor (lisinopril, n  9,054) arms of the trial were
eported (94). To recap, the primary outcome of ALLHAT
as combined fatal coronary heart disease or nonfatal
yocardial infarction. The secondary outcomes included
ll-cause mortality, stroke, combined CVD, end-stage renal
isease, cancer, and gastrointestinal bleeding. Over a mean
ollow-up of 4.9 years, BP control was similar in nonblack
atients, but the CCB provided better BP control in black
atients, consistent with the National Institute for Health
nd Clinical Excellence/British Hypertension Society
NICE/BHS) guideline recommendations (see the follow-
ng text). No significant differences were found between
reatment groups for the primary outcome, all-cause mor-
ality, end-stage renal disease, or cancer. Stroke rates were
igher on lisinopril in black subjects, consistent with the
oorer BP control with the ACE inhibitor in this group, but
ere similar in nonblack subjects in whom BP control was
imilar. Overall, the rates of combined CVD events were
igher with the ACE inhibitor because of higher rates for
trokes, peripheral arterial disease, and angina. As expected,
he rates of heart failure were lower with lisinopril. Gastro-
ntestinal bleeds and angioedema were higher on lisinopril.
his finding, along with the finding of a neutral effect on
ancer rates between treatment arms, is important because it
ismisses prior concerns about higher rates of cancer and
astrointestinal bleeding with CCBs that emerged from
arlier case-control studies, highlighting that such studies
re riddled with confounding factors that cannot be ade-
uately controlled and should never be used to inform
ealth policy, or worst, alarm patients. This analysis also
uggests that the combination of an ACE inhibitor and a
CB might be a particularly happy marriage for BP
owering and CVD prevention.
Lowering BP in people with diabetes significantly re-
uces the risk of CVD morbidity and mortality and micro-
ascular disease. The recently reported ADVANCE (Ac-
ion in Diabetes and Vascular disease: preterAx and
iamicroN-MR Controlled Evaluation) trial examined the
mpact of an ACE inhibitor (perindopril)/thiazide-type
iuretic (indapamide) combination versus placebo on top of
onventional therapy on vascular events in 11,140 people
ith type 2 diabetes (95). An important design feature of ahis trial was the fact that the BP-lowering combination
herapy was added irrespective of baseline BP levels or the
se of other BP lowering drugs. The primary end point was
composite of major macrovascular and microvascular
vents, including death of cardiovascular disease, nonfatal
troke or nonfatal myocardial infarction, and new or wors-
ning renal or diabetic eye disease, over a mean follow-up of
.3 years. The active therapy was associated with a lower BP
5.6/2.2 mm Hg) versus placebo treatment. This mod-
st BP reduction was associated a significant 9% risk
eduction in major macrovascular and microvascular events,
n 18% reduction in cardiovascular death, and a 14%
eduction in all-cause mortality. Importantly, there was no
vidence that the benefits of additional BP-lowering ther-
py differed according to initial BP level—in other words,
ven those within lowest BP strata at baseline experienced a
imilar relative risk reduction to those in the highest BP
trata. Moreover, the lowest BP strata included patients
hose BP was already below the currently recommended
reatment target for type 2 diabetes (130/80 mm Hg). It
s also important to note that this result was achieved in a
opulation of patients with high concomitant use of statins,
ntiplatelet drugs, ACE inhibition, and good glycemic
ontrol, in both arms of the trial. This trial provides the
trongest evidence yet to support the safety, tolerability, and
fficacy of a “lower is better” philosophy for BP control in
eople with diabetes and that the modern treatment goal
hould perhaps be “the lowest pressure the patient will
olerate without an adverse impact on function.”
ypertension Treatment Guidelines
number of treatment guidelines related to the treatment
f hypertension have recently been published. In the United
ingdom, the NICE, working in collaboration with the
HS, issued an updated guideline for the treatment of
ypertension in primary care in June 2006 (96,97). This
uideline was the result of a comprehensive systematic
eview of clinical trial data and concluded that initial therapy
or hypertension should be with an A drug (ACE inhibitor,
r ARB if an ACE inhibitor was not tolerated) in younger,
onblack people, that is, 55 years, and a CCB (C drug) or
hiazide-type diuretic (D drug) drug in older people, or
lack subjects at any age, to guarantee the most effective
P-lowering efficacy with initial therapy. This guideline
ent beyond usual guideline recommendations by providing
ery specific recommendations for preferred combinations
f therapy if BP was not controlled with monotherapy,
otably A  C or A  D at step 2, and A  C  D at step
. Beyond step 3, further diuretic therapy, for example,
igher doses of thiazide-type diuretic, or addition of an-
ther diuretic, for example, low dose spironolactone, was
ecommended. A bold and controversial recommendation
f this guideline was the removal of beta-blockers as a
referred routine therapy for hypertension because the data
nalysis had suggested that this class of drugs was: 1) less
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Year in Hypertension May 6, 2008:1803–17ffective at preventing stroke than other treatments; 2) no
ore effective in the primary prevention of myocardial
nfarction (despite popular dogma); 3) was more likely to
nduce new-onset diabetes; and 4) the least cost-effective
reatment option for routine hypertension. This does not
reclude the use of beta-blockers at step 4, or in patients
ho had a specific indication for beta-blockade, for exam-
le, symptomatic angina, after myocardial infarction, or in
hronic stable heart failure. This view of the NICE/BHS
uideline regarding the routine use of beta-blockers for
ypertension was supported by a subsequent Cochrane
eview (98) and other reviews and editorials (99 –102). The
etabolic effects of beta-blockers, and in particular their
dverse effect on weight loss, also was recently reported ( 103).
The European Society of Cardiology (ESC), working in
ollaboration with the European Society of Hypertension
ESH), also released new guidelines for the treatment of
ypertension in 2007 (104). This guideline provides a very
omprehensive review of the assessment of hypertensive
atients with regard to target organ damage and cardiovas-
ular risk and also contains specific recommendations of BP
easurement, investigations of secondary hypertension, and
rug treatment in special situations, for example, pregnancy,
he elderly, stroke, renal disease, and so on. This guideline
oes not define a preferred initial therapy for routine
ypertension. An important aspect of the ESC/ESH guide-
ine is continued recognition in Europe of the importance of
argeting cardiovascular disease risk and not just BP when
onsidering the treatment of hypertension in an individual
atient—advocating the more widespread use of statin
herapy in particular, and antiplatelet therapy when safe and
ppropriate, to optimize cardiovascular risk reduction.
The World Health Organization (WHO), in collabora-
ion with the International Society of Hypertension (ISH),
ave also focused attention on the need to consider total
VD risk and have provided a new WHO/ISH CVD risk
hart that could be readily applied to low-income and
iddle-income countries (105).
With regard to CVD risk, the recent position statement
rom the American Heart Association on the treatment of
ypertension for the prevention and management of isch-
mic heart disease (IHD) was disappointing (106). This
7-page document focused on differences between BP-
owering drugs and addressed whether some drugs might
go beyond blood pressure” with regard to the prevention of
HD. Surely this missed a key opportunity to give promi-
ence to the importance of statin therapy as the most
ffective means of going “beyond blood pressure” for the
revention of IHD and stroke in people with treated
ypertension? Remarkably, the authors did concede that
There are no special contraindications in hypertensive patients
o the use of. . .lipid-lowering agents for the management of
TEMI [ST-segment elevation myocardial infarction].” Con-
raindications! I would suggest that a physician would struggle
o justify not using statin therapy in such patients and in others
ith hypertension! A good example, if we needed another one,hy modern guidance must be focused on total CVD risk
ssessment and intervention.
ecent Reviews of Hypertension
n addition to the topics covered in this overview of the year
n hypertension, there have been a number of very good
eviews and topical overviews of different aspects of hyper-
ension. The topics include atherosclerotic renovascular
isease and related ongoing trials (107), clinical aspects of
hronic hypertension in pregnancy (108), isolated systolic
ypertension in the elderly (109), a review of the presenta-
ion and clinical diagnosis and treatment of pheochromo-
ytoma (110,111), the effects of nonsteroidal anti-
nflammatory drugs on BP (112), the role of the
ympathetic nervous system in the pathogenesis of meta-
olic syndrome (113), and the eye in hypertension (114),
long with a comprehensive seminar in hypertension (115).
onclusions
he past year has been an eventful one for hypertension
esearch, and 2008 promises to be an even more eventful
ear, with a record number of long-awaited major clinical
utcome trials due to report their findings. Findings that
hould answer some key questions: 1) What is the preferred
ombination of antihypertensive therapy for hypertension,
he routine use of an ACE inhibitor plus a thiazide diuretic
r a more contemporary combination of ACE inhibition
ith a CCB? 2) Is there any difference between ACE-
nhibitor-based versus ARB-based therapy for cardiovascu-
ar protection, and does the combination of these agents
rovide more (or less)? 3) What are the benefits of BP
owering in the very elderly? 4) What is the optimal
reatment for diastolic heart disease in hypertensive pa-
ients? 5) Further major studies of BP lowering in acute
troke and the secondary prevention of stroke. Thus, there
ill be no shortage of information for next year’s review of
he year in hypertension, which will focus on the implica-
ions of these key clinical trials.
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